The abstract is read at the publisher; the summary is JClub's.
In hospitalized adults with advanced HIV disease in sub-Saharan Africa, tuberculosis pre-test probability often exceeds the therapeutic threshold, supporting earlier empiric antituberculous therapy even without confirmatory testing.
- Why it matters: High mortality in this population is driven largely by disseminated, frequently undiagnosed tuberculosis, while waiting for diagnosis can delay treatment and worsen outcomes.
- What they did: The authors apply the therapeutic threshold framework to severely ill inpatients with advanced HIV disease, integrating evidence that short delays in antituberculous therapy are linked to substantial mortality increases, and weighing toxicity and overtreatment concerns.
- The result: They argue that short-term empiric antituberculous therapy appears safe and may be outweighed by harms of untreated disease, motivating earlier empiric treatment with reassessment and mortality-powered randomized trials.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.